Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Individual healthcare-seeking pathways for tuberculosis in Nigeria’s private sector during the COVID-19 pandemic

View ORCID ProfileCharity Oga-Omenka, View ORCID ProfileLauren Rosapep, View ORCID ProfileLavanya Huria, View ORCID ProfileNathaly Aguilera Vasquez, View ORCID ProfileBolanle Olusola-Faleye, Mohammad Abdullah Heel Kafi, View ORCID ProfileAngelina Sassi, Chimdi Nwosu, View ORCID ProfileBenjamin Johns, Abdu Adamu, View ORCID ProfileObioma Chijioke-Akaniro, View ORCID ProfileChukwuma Anyaike, View ORCID ProfileMadhukar Pai
doi: https://doi.org/10.1101/2023.06.13.23291334
Charity Oga-Omenka
1School of Public Health Sciences, University of Waterloo, Ontario, Canada
2McGill International TB Centre, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charity Oga-Omenka
  • For correspondence: cogaomenka{at}uwaterloo.ca
Lauren Rosapep
3Sustaining Health Outcomes through the Private Sector (SHOPS) Plus/Abt Associates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lauren Rosapep
Lavanya Huria
2McGill International TB Centre, Montreal, Canada
4Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lavanya Huria
Nathaly Aguilera Vasquez
2McGill International TB Centre, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathaly Aguilera Vasquez
Bolanle Olusola-Faleye
3Sustaining Health Outcomes through the Private Sector (SHOPS) Plus/Abt Associates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bolanle Olusola-Faleye
Mohammad Abdullah Heel Kafi
2McGill International TB Centre, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelina Sassi
2McGill International TB Centre, Montreal, Canada
4Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angelina Sassi
Chimdi Nwosu
5VizSight Analytics Inc, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Johns
3Sustaining Health Outcomes through the Private Sector (SHOPS) Plus/Abt Associates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin Johns
Abdu Adamu
3Sustaining Health Outcomes through the Private Sector (SHOPS) Plus/Abt Associates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Obioma Chijioke-Akaniro
6National Tuberculosis and Leprosy Control Program, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Obioma Chijioke-Akaniro
Chukwuma Anyaike
6National Tuberculosis and Leprosy Control Program, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chukwuma Anyaike
Madhukar Pai
2McGill International TB Centre, Montreal, Canada
3Sustaining Health Outcomes through the Private Sector (SHOPS) Plus/Abt Associates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Madhukar Pai
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Pre-COVID-19, individuals with TB in Nigeria were often underdiagnosed and untreated. Care for TB was mostly in the public sector while only 15% of new cases in 2019 were from the private sector. Reports highlighted challenges in accessing care in the private sector, which accounted for 67% of all initial care-seeking. Our study examined patients’ health seeking pathways for TB in Nigeria’s private sector, and explored any changes to care pathways during COVID, based on patients’ perspectives.

Design/Methods We conducted 180 cross-sectional surveys and 20 in-depth interviews with individuals having chest symptoms attending 18 high volume private clinics and hospitals in Kano and Lagos States. Questions focused on sociodemographic characteristics, health-seeking behavior and pathways to care during the COVID-19 periods. All surveys and interviews were conducted in May 2021.

Results Most participants were male (n=111, 62%), with average age of 37. Half (n=96, 53.4%) sought healthcare within a week of symptoms, while few (n=20, 11.1%) waited over 2 months. TB positive individuals had more health-seeking delays, and TB negative had more provider delays. On average, participants visited 2 providers in Kano and 1.69 in Lagos, with 61 (75%) in Kano and 48 (59%) in Lagos visiting other providers before the recruitment facility. Private providers were the initial encounters for most participants (n=60 or 66.7% in Kano, n-83 or 92.3% in Lagos). Most respondents (164 or 91%) experienced short-lived pandemic-related restrictions, particularly during the lockdowns, affecting access to transportation, and closed facilities.

Conclusions This study showed a few challenges in accessing TB healthcare in Nigeria, necessitating continued investment in healthcare infrastructure and resources, particularly in the private sector. Understanding the different care pathways and delays in care provides opportunities for targeted interventions to improve deployment of services closer to where patients first seek care.

Background

Before the COVID-19 pandemic, tuberculosis (TB) was the leading cause of infectious disease deaths globally [1]. Of the 10.6 million estimated cases in 2021 worldwide, only 6.4 million (60%) were diagnosed and notified [1]. Since the COVID-19 pandemic, global TB notifications and treatment have dropped, and deaths increased, erasing progress made in the last two decades [1]. This decline suggests increases in community transmission and infections.

Globally, several high burden TB countries reported that the COVID-19 pandemic and control measures significantly impacted case notifications, treatment, and other services for TB [1–3]. The End TB Strategies calls for early diagnosis and treatment of TB [4], yet delays are persistent in many high burden countries, including Nigeria, particularly in the private sector [5–8]. Extended delays are associated with increased risks of transmission, morbidity, and mortality [9–12].

Patient pathways analyses are useful approaches to understanding patients’ care seeking patterns and how they access available services [13, 14]. Individual patient pathway analyses can provide insights on the number of attempts individuals make to find TB care, and the missed opportunities for appropriate TB care. This information is necessary to surmount the problem of poor access to high quality TB care and is key to finding the missing millions of TB cases that go undiagnosed globally every year [1, 13, 15]. Pathway analyses have been used to highlight misalignment between demand and available resources at the macro level [14], or show the different care-seeking decisions at the micro level, as well as the types and numbers of providers that patients seek care with before getting diagnosed and treated [16, 17]. Several aspects of care pathways have been highlighted in literature, including time delays between symptom recognition, health seeking, diagnosis and treatment, as well as the number of healthcare encounters, type and sector of providers encountered, and point of diagnosis [14, 17, 18].

Nigeria, a high burden TB country, had an estimated 467,000 incident cases in 2021[1]. Case notification for TB in Nigeria has come mainly from the public sector. Only 15% of new TB cases in 2019 were reported from the private sector, even though it accounts for approximately 67% of initial TB care-seeking [19]. Nigeria recorded 88,388 confirmed cases of COVID-19 in 2020, with over 266,000 cases as of December 2022 [20]. During the initial lockdowns in March-April 2020, there were several reports indicating significant disruptions to TB services [21–24]. Nigeria and other high burden TB countries reported delays in care-seeking for respiratory symptoms due to fear of COVID-19 diagnosis [23, 25–28]. However, TB case finding began to rebound in June 2020 and by the second wave in December 2020 to March 2021, TB notifications had fully recovered to pre-pandemic levels [24]. This made Nigeria an outlier for pandemic recovery among other high-burden countries [1]. Private sector notifications significantly increased, contributing to the overall rise in TB notifications since 2020 [1, 29]. It remains unclear if there are long-lasting impacts of COVID-19 on healthcare seeking for chest symptoms in Nigeria’s private healthcare sector.

The USAID-funded Strengthening Health Outcomes through the Private Sector (SHOPS) Plus Nigeria project aimed to strengthen the private sector’s capacity to detect and treat TB in alignment with international standards and the national TB control plan. By training and supporting over 2,900 private providers, including clinical providers, laboratories, community pharmacists and proprietary patent medicine vendors (PPMVs) in Lagos and Kano States, the project contributed to substantial increases in private sector TB notifications between 2017 and 2020 [30]. Our study utilized cross sectional surveys and qualitative interviews with individuals with diagnosed and presumptive TB within the SHOPS Plus network in Kano and Lagos, to assess how healthcare seeking and pathways may have changed in the private sector. This study aimed to examine in Nigeria whether there were any long-lasting impacts of COVID on care-seeking given that the apparent disruptions in care were relatively short-lived.

Conceptual framework

Our conceptual framework (Fig 1) is derived from existing literature [17, 31–33] and highlights two main types of delays along pathways to TB care: health-seeking and health system delays. Health-seeking delays refer to the time it takes from symptom onset to patients recognizing their symptoms and seeking care from a healthcare provider. Health-seeking is influenced by lack of TB knowledge, stigma, cost of seeking care, amongst other factors. Health system delays occur once patients have sought care and can be further divided into provider delays and treatment delays. Provider delays occur healthcare providers delay diagnosis due to low index of suspicion of TB, limited diagnostic tools, misdiagnosis, or delays in making referrals, conducting tests or transmitting results. Treatment delays occur when patients are diagnosed with TB, but there is a delay in initiating treatment, due to a lack of medication or equipment, insufficient staff, or poor communication between providers and patients. Diagnostic delays refer to the time it takes from the onset of symptoms (individual-level) to the confirmation of TB diagnosis (health-system level). Lack of knowledge of TB (symptoms, diagnosis and treatment) is a common factor contributing to diagnostic delay [5].

Figure 1:
  • Download figure
  • Open in new tab
Figure 1:

Conceptual framework on types of delays along the TB care cascade [17, 31-33]

There is some consensus that delays should not exceed 2-4 weeks from onset of symptoms to seek care, 3-7 days for testing (provider delay) using the current WHO-recommended TB diagnostics, and 1-2 days for treatment initiation to optimise patient outcomes [34–36]. The WHO considers as unethical any delay in treatment initiation in the presence of a positive diagnosis or a strong presumption of TB [35].

Previous studies conducted in Lagos [5] and rural Nigeria [7] found that health-seeking delays were more common than provider delays, contributing more to overall total delay. The factors associated with these delays can be categorized as individual-level (knowledge, attitudes, and behaviours), or structural-level (relating to healthcare facilities, providers, doctors, etc.).

These delays can lead to 3 major gaps or missed opportunities in accessing TB care: Gap 1 includes those who never access TB testing, Gap 2 are those who access testing but are not diagnosed, and Gap 3 includes those diagnosed but not treated. These gaps result in prolonged illness, disease transmission, increased risk of drug-resistant TB, and death [1, 32, 33]. Studies done in Nigeria before the pandemic identified Gap 1 as the biggest challenge in TB control, followed by Gap 2 [6, 32, 37, 38].

Methods

Study design, population and sampling

We conducted pathway analyses using mixed methods, to survey 180 individuals and conduct 20 in-depth interviews during the second COVID-19 wave in May 2021 (Appendix 1). This study was part of a larger research project in 3 high burden countries. We previously published the timelines of the COVID epi-curve, TB notifications and the timing of our data collection in Nigeria [24]. Our study took place among individuals seeking TB care in 18 private facilities in Kano and Lagos, the states with the highest TB burden and levels of private sector activity [30], and with estimated population of 14.7 million and 13 million respectively in 2021 [39]. We sampled active providers within the SHOPS Plus program network, 1,084 in Kano and 1,317 in Lagos, out of which were 217 and 472 clinical facilities respectively.

To ensure even geographic distribution of recruitment facilities within the states, we used a non-probabilistic quota sampling to select 18 high volume TB clinical facilities within the SHOPS Plus network (Appendix 2). We prioritized higher volume facilities to minimize overall facility and network burden and increase recruitment efficiency. We included the three highest volume facilities (by total TB notifications) in each senatorial zone, ensuring only one facility per local government areas (LGA), resulting in a total of nine facilities per state.

We visited each consenting recruitment facility and developed a list of eligible patients from the facility’s National TB program mandated presumptive and treatment registers, from which participants were randomly selected. Two types of patients were recruited – patients confirmed to be negative for TB (negative sputum test result in the register); and patients recently diagnosed (positive sputum test result for TB) receiving or scheduled for TB treatment within the same facility. All recruited patients were over 18 years old, HIV negative, and had confirmed results between January and May 2021 (to minimize survey recall bias). We excluded previously confirmed COVID-19 cases, individuals unable to provide a sputum sample, patients initiating treatment at another facility, and those with missing sputum results or a history of anti-TB treatment in the past 6 months. Within each recruitment facility, we surveyed ten participants and conducted additional in-depth interviews 1-2 participants.

Eligible individuals were contacted by facility staff to explain the study’s purpose and assess their initial willingness to participate. A date, time and place (the clinical facility, patient’s home, or place of work) were agreed upon for the survey and interviews.

Data collection

Our study instruments focused on various aspects, including the onset of symptoms and care-seeking pathway, interactions with healthcare providers from initial encounters to TB diagnosis and treatment initiation, healthcare decision-making and use during COVID-19, perspectives on the pandemic, and the impact of COVID-19 on patient care.

To ensure accuracy, the study tools were translated into local languages (Yoruba and Hausa), back translated to English, pretested and piloted. Survey instruments were programmed into SurveyCTO and field officers were trained for each survey, and only those who performed satisfactorily were deployed. Precautionary measures against COVID-19 were implemented prior to survey implementation, and verbal informed consent was obtained before interviews. Transport costs were reimbursed for participants who preferred interviews in the facility. Completed tools were uploaded to the SurveyCTO server. We maximally varied interview participants by location, TB status, and gender.

Interviews, which lasted 24 to 55 minutes on average, were conducted in English, with respondents encouraged to request translation into or respond in Nigerian Pidgin, Yoruba or Hausa if needed. All interviews were audio-recorded and transcribed, with translations from Yoruba and Hausa languages by fluent translators.

Data analysis and pathway construction

Our analysis involved descriptive statistics, construction of care pathways and logistic regressions. We weighted the data to address non-response and ensure the similarity between responders and non-responders in terms of background characteristics [40, 41]. We used logistic regression with covariates to calculate non-response weight, and predictive probabilities of survey response were calculated derived. Unweighted mean of probabilities matched the 70% unweighted response rate in dataset. [3]. The non-response weight was determined by inverting the predictive probabilities [41], resulting in a sum equal to the sample size.

We used descriptive statistics to analyze demographic characteristics of non-responders, considering both weighted and unweighted data. Univariate Pearson’s chi-square (Χ2) tests assessed associations between individual characteristics, TB status, private sector TB care delivery, impact of COVID, using weighted and unweighted cases.

We constructed individual patient-level pathways using stacked bar charts, which depict the chronological order in which individuals encountered various types of healthcare providers leading up to diagnosis and treatment. To create these sequencing charts, we accounted for points of diagnosis (including laboratories, community outreaches and traditional healers) even where the participants themselves did not acknowledge these as unique provider encounters.

Logistic regressions (weighted) were utilized to examine the relationship between patients’ characteristics and symptoms with their utilisation of private providers as the initial point of seeking healthcare, the number of provider encounters, as well as the use of multiple providers. We reported the odds ratio with 95% confidence intervals, considering a p-value of < 0.05 as statistically significant.

Statistical analysis was performed using the open-source programming language R (version 4.0.3) and R Studio (version 1.4.1106). Transcripts were coded inductively and deductively by two coauthors, CO and LH, using the Quirkos software (version 1.61), with an initial codebook developed from 2 transcripts. Codes and themes were double-checked by CO, and the thematic analysis reviewed by the research team for alignment with study objectives.

Ethical considerations

Our study received ethical approval from the McGill University Health Centre (MUHC) Research Ethics Board (REB), with approval number Covid BMGF / 2021-7197. We also obtained approval from the health research ethics committee (HREC) in both States, including from the Lagos State University Teaching Hospital (LASUTH) and Kano State Ministry of Health (MoH). We also obtained letters of introduction from Abt Associates to the MoH, National Association of Patent and Proprietary Medicines (NAPPMED), Association of Community Pharmacists in Nigeria (ACPN), and heads of the target facilities. All survey and interview participants gave written or verbal consent.

Results

Characteristics of participants and non-response

Out of 337 patients contacted (Appendix 3), 180 participants completed the survey and 20 participated in the in-depth interviews. Higher non-response rates were observed among participants from Kano State (62.5%) and those who tested negative for TB (54%). Gender and age distributions were similar for both surveyed and non-surveyed participants, except for the 55+ age group, where non-surveyed rate was higher (18.8% vs 12.2%).

The participants (Table 1) were predominantly male (62%), married (53%) especially in Kano State (58 vs 49% in Lagos), with an average age of 37 years. Participants had in Kano had more dependent relatives on average (6) than in Lagos (3). Larger proportions were self-employed (43%), had a secondary school education (34%). More participants lived within a 2km radius from a public facility (48%), or a private facility (54%).

View this table:
  • View inline
  • View popup
Table 1:

Characteristics of surveyed participants by States [N = 180]

Health-seeking and health system delays

Half of the 180 participants (n=96, 53.4%) sought care with a provider within a week of noticing their symptoms, with 17.8% seeking care within the first 2 days (Table 2). Only very few patients (n=20, 11.1%) waited for 2 months and above before seeking care.

View this table:
  • View inline
  • View popup
Table 2:

Delays, care pathway, missed opportunities and the impact of COVID-19

Health-seeking and provider delays were experienced more by participants diagnosed with TB (38% and 43% Fig 2a), with 14% of them experiencing treatment delays. Participants from Lagos (29%, Fig 2b) experienced more health-seeking delays. Provider and treatment delays were more in Kano (40% and 10%) compared to in Lagos (28% and 4%).

Figure 2:
  • Download figure
  • Open in new tab
Figure 2:

The proportion of participants experiencing different types of delays (a) by TB status and (b) by State

Out of 180 participants, (n=71, 39%) had their sole provider encounter at the study recruitment facilities (private clinics or hospitals), which included 3 individuals who had previously been diagnosed at community outreaches (Table 2). Fig 2c presents the number of participants and the varying time delays at each provider encounter. Among 109 participants who visited other providers before the recruitment facility, 55 had their initial encounter within a week, 25 waited 1-4 weeks, and 29 waited over a month. Out of the 33 who consulted two additional providers, 8 waited 1-7 days from the first encounter, 16 waited 1-4 weeks, and 9 waited for over a month. Among 8 who visited 3 providers, 4 waited 1-7 days following the second encounter, 1 waited 1-4 weeks, and 3 waited for more than a month. Of the 2 who visited 4 providers, 1 waited 1-7 days, and the other waited 1-2 months.

Figure 2c:
  • Download figure
  • Open in new tab
Figure 2c:

Patterns of delays with each additional provider encounter for 180 participants

At the recruitment facility, 96 of 180 participants waited 1-7days, 38 waited 1-4 weeks and 46 waited more than 1 month. Of those who waited more than a month, the majority were individuals who had visited other providers. Delays between encounters increase with each additional provider encounter, particularly with the 3rd and 4th encounters. Most TB patients were initiated on treatment within 2 days of diagnosis (n=34, 75% in Kano; n=32, 73% in Lagos).

From the qualitative interviews, many participants, regardless of TB status, reported health-seeking delays as they waited until their symptoms became prolonged. Symptom minimisation was a very common theme as most participants did not take coughing to be a serious health issue, at first (Fig 3). Participants assumed that the cough would subside, and participants self-medicated. Some participants mentioned that they were also afraid of getting infected with or being diagnosed with COVID-19. Provider delays were mostly due to misdiagnosis and delayed referral to TB testing sites. All TB patients interviewed in Kano and Lagos were initiated on treatment within 2 days of diagnosis.

Figure 3:
  • Download figure
  • Open in new tab
Figure 3:

Qualitative themes on pathways to TB care

Individual patient pathways

On average, participants had 2 provider encounters in Kano, and 1.69 in Lagos, with a median of 2 in both States before visiting the recruitment facility (Appendix 4). Participants who visited the network of private hospitals and clinics had the fewest average encounters (mean of 1.10) compared to other providers (pharmacies or vendors = 2.35, public clinic = 3.00, traditional healers = 3.00, private clinic=3.33). Our survey revealed that the majority (n=109, 61%) patients sought care from multiple providers. Twenty-five percent of participants in Kano, and 41% in Lagos sought care only in the recruitment facility.

Our pathway sequencing charts (Fig 4a and 4b) identified 31 and 16 different patterns in Kano and Lagos, respectively, of progressive provider encounters. Participants in Kano, irrespective of their diagnosis, had more encounters and more variation in health-seeking than in Lagos. The largest share of participants in Kano used one additional provider (n=42, 46.6%) while for Lagos, the majority (n=42, 46.6%) used the recruitment facility (RF) exclusively.

Fig 4a and 4b:
  • Download figure
  • Open in new tab
Fig 4a and 4b:
  • Download figure
  • Open in new tab
Fig 4a and 4b:

Pathway sequences for all survey participants and those in each state

Fig 4c showed 53 different sequencing patterns for all 180 survey participants, and included points of diagnosis, as well as the proportions who ended up with a negative diagnosis. The majority of participants (n=165, 91.6%) were diagnosed (with or without TB) at the recruitment facilities. All diagnosis points were clinical facilities (private or public). All TB positive participants (n=90) were initiated on treatment in the private hospitals or private clinics that were our recruitment facilities.

The qualitative data (Fig 3, Appendix 5) shows many participants used a private provider first, because these providers were more accessible and convenient, and public hospitals were congested. In terms of choice of provider, this was either because of proximity, prior relationship with provider, cost considerations or due to referral or contact tracing from someone the participant knew. Several of those with more than one encounter said that the medicine store was their first port of call. Many participants visited multiple providers as their symptoms worsened, particularly those with TB. For participants diagnosed, once they were told they had TB, several said they were placed on treatment on the same or next day. Although the pathways to diagnosis were cumbersome for many, they expressed satisfaction with the care they received afterwards. The majority of themes regarding treatment were positive experiences after diagnosis.

Impact of COVID-19

At the time of our survey, 74 (41%) participants said it was easier to access healthcare, while 46 (26%) said it was still difficult. Most respondents (164 or 91%) experienced lockdowns or other pandemic-related restrictions, which affected transportation to seek care for 41 (23%), closed facilities for 27 (15%) and longer waiting times for 27 (15%) of them. However, at the time of the survey, most respondents said they were more willing (118 or 66%) to seek healthcare, compared to before the pandemic.

From the in-depth interviews, early on in the pandemic, participants were concerned about the rising deaths due to COVID-19, which discouraged them from going to a clinic or hospital. Participants didn’t want to get infected, but more importantly, they didn’t want to be forced to take a diagnostic test for COVID-19, test positive, then have to quarantine, which was the practice in many public hospitals at the time. A few participants said transport challenges during the lockdown period hampered their access to care. Participants also mentioned provider attitudes during the early phase of the pandemic as being fearful or unhelpful.

Determinants and factors influencing private sector use and number of encounters

We looked at predictors for two outcome variables – 1) Choosing to use a private facility as their first healthcare contact 2) Using more than one provider from symptom onset. We also present the adjusted regression coefficient for the number of provider encounters.

When we looked at the predictors for participants choosing to use a private facility as their first healthcare contact (Fig 5a), we found that participants in Lagos State were more likely (OR = 8.97, 95% CI: 2.90 – 27.65). Those who were self-employed (OR = 0.22, 95% CI: 0.06 – 0.76), and those presenting with rashes and allergies (OR = 0.16, 95% CI: 0.03 – 0.79), were less likely to use private providers first. No other variables, including age, gender, TB status or symptoms were significant. The only statistically significant determinant of using more than one provider (Fig 5b) was having difficulty in breathing as a symptom (OR = 4.69, 95% CI: 1.42 – 15.51).

Figure 5a:
  • Download figure
  • Open in new tab
Figure 5a:

Determinants of using the private sector as first provider contact

Figure 5b:
  • Download figure
  • Open in new tab
Figure 5b:

Determinants of using more than one provider after symptoms

Discussion

In our study of patient pathways within the private sector in two Nigerian states, we found that individuals with chest symptoms experienced relatively short pathways. The study was conducted in a unique context, differing from the typical urban areas in Nigeria. The sampled providers belonged within the SHOPS Plus network, which provided extensive support to private sector facilities, ensuring efficient referral systems, availability of laboratory equipment and medications, and community engagement for case identification. Even within this context, patients faced some health-seeking and provider delays.

Health-seeking and health system delays

Our investigation showed several challenges associated with health-seeking and provider delays. However, once individuals with TB were identified and given a definitive diagnosis, their experience with the healthcare provider was much more positive and timelier than their experience before diagnosis, agreeing with several studies in Nigeria and other high burden settings [32, 38, 42]. Of the 90 TB positive participants, majority (n=66, 73%) and all of the qualitative interview participants were treated within 2 days of diagnosis, contributing to their feelings of relief or gratitude, because they finally felt, ‘seen’ by the healthcare system.

Individual pathways and private sector use

Among the 180 participants and excluding the 71 who sought care first at the recruitment facility, the majority (74 out of 109) initially sought care in private facilities. Some studies in Nigeria and in similar high burden TB countries have found that patients seek care first in drug stores or with traditional healers before clinics or hospitals [5, 7, 43–45], particularly if they were ‘only’ coughing [44, 46].

In our sample of networked providers, pharmacies and medicine vendors had higher rates of providing or referring patients for TB testing and treatment, while the private hospitals and clinics provided appropriate care for every patient who visited them. This was due to the support this network of providers received, and the fact that most of the drug stores in our sample were located close to the private clinics and hospitals in the same network. Few studies have looked at the differences in referrals between different types of private providers; however, studies in Nigeria and in similar settings show that case notifications and referrals for TB care from the private sector has been historically very low and in need of intervention [42-44, 47-49]. The SHOPS Plus project, in collaboration with other stakeholders in Nigeria, have implemented several strategies to strengthen linkages between the private sector and the public TB delivery system [50].

Several studies found that individuals with chest symptoms are very likely to minimise symptoms like cough or fever [38, 51–53]. Similar results have been reported in other high-burden TB settings where symptoms like weight loss were associated with faster care-seeking, in comparison to cough and fever which were perceived to be ‘normal’ [7, 51, 52, 54]. In some settings, fever or headaches have been found to shorten delays [55–57].

In charting patient pathways, our results show that all the patients who chose a private hospital (including recruitment facility) as their first or second provider did not use an additional provider. This was likely influenced by the fact that our recruitment facilities, which were supported sites, represented the first facility for 71 (40%) of all participants. We also found a similar pattern among patients who used a private hospital as second provider - of not going to another provider. These findings agree with studies from several high burden TB countries, where hospitals, in public and private sector, missed diagnosing TB patients [49, 58–60]. A pre-covid study in Nigeria found patients having up to 5 pre-NTP provider visits [61]

Qualitative themes related to misdiagnosis, lack of TB testing or referrals to other facilities were also common. Congestion and waiting times in health facilities also discouraged participants from seeking care, but that finding might have been a result of our purposive sampling in high-volume facilities.

While Nigeria has shown remarkable increases in number of annual case notifications [1], there are still approximately 208,000 missing cases estimated annually. Our findings are in concordance with several studies on TB care cascade showing that access to diagnostic services, or Gap 1, is the largest gap in the care cascade [32, 33, 42, 62]. Participants faced several barriers in accessing diagnostic services, especially during the start of the COVID-19 pandemic, and yet the responsibility for being diagnosed rests mostly on the patient, just like before the pandemic [38]. Our findings agree with other studies showing TB positive participants face longer diagnostic delays [32, 33, 38, 63, 64], often due to lack of access to a diagnostic test [32].

Determinants of private sector use and numbers of providers

Our logistic regressions identified factors influencing private sector use and total number of providers encountered within the context of our study. Our participants were all recruited within a network of dedicated private providers in Kano and Lagos, making them distinct from the general population in terms of their inclination and capacity to utilize private healthcare. Participants in Lagos State were more likely to use the private sector first (93%) before going to the public sector, compared to 67% in Kano. This might be because self-employed individuals might be more flexible with the time required to seek, and the lower cost of public healthcare. Two studies in India found young age, females, higher level of education and income group associated with private sector use [65, 66]. Several studies in Nigeria and other countries have suggested that patients are reluctant to use the public sector because of longer waiting times, lower quality of care, or poor provider attitudes, while on the contrary, private facilities have a reputation of better quality at a higher cost [38, 67, 68].

Patients who had difficulty in breathing as a symptom were more likely to use more than one provider. Several studies have shown that patients with chest symptoms delay care-seeking for a variety of reasons and also contact several private providers before diagnosis [69–72]. This is likely because of the symptom minimization observed in several countries, where patients do not immediately seek hospital care for cough until symptoms deteriorate, preferring to self-medicate, or visit informal providers [38, 46, 72–74]. The use of more than one provider has also been shown to be partly responsible for prolonged delays in TB diagnosis and treatment [5, 75–77].

Impact of COVID-19

Participants in our study reported that the impact of COVID-19 on care-seeking was mostly felt during the lockdown periods, with a subsequent recovery to pre-pandemic levels. This finding aligns with the quick recovery of TB case notification in Nigeria compared to other countries [1]. Disruptions to TB services have been widely documented in many high-burden settings [28, 78, 79]. Lockdown and the movement restrictions posed barriers to accessing care, leading to delayed care seeking due to difficulties in finding affordable transportation. Other concerns included the affordability of hospital care during the lockdown, fear of being diagnosed with COVID-19 or overburdened public hospitals. Some participants perceived their symptoms to be minor, further contributing to delayed care-seeking. Some participants narrated fearful healthcare workers’ attitudes towards them, particularly during the early days of the pandemic.

From the survey responses, most participants indicated that COVID did not affect their care-seeking beyond the lockdown period. However, the qualitative data showed fear of COVID was a predominant theme resulting in delayed care-seeking, albeit short-lived.

Limitations

Our study has a few limitations. First, we were unable to calculate total provider delays across all provider encounters as our time measure were categorical and not exact dates. We also did not capture data on the total visits for each provider, as this would have provided a greater understanding of the total number of times participants sought care for their symptoms. Our analysis is limited by non-random purposive sampling for selecting facilities and patients and selection bias. We cannot say whether a study including patients diagnosed in the public sector or outside of the network of providers supported by the SHOPS Plus program will show similar results. There was also no way to determine exactly if our sampled facilities were representative of the distribution of all facilities in Kano and Lagos. Finally, as patients were asked to recall events that had happened earlier, there might have been some recall bias in the responses. We attempted to mitigate this effect by only selecting recently tested patients, with encounters with the facilities dating back no further than January of 2021, or 5 months before our data collection.

Conclusion

Our patient pathway study in two major cities in Nigeria showed relative shorter individual pathways to care, given the unique context. It emphasizes the importance of involving lower cadres in case identification and referral efforts, irrespective of the sector. Despite well-funded initiatives, delays persist, albeit potentially more manageable. Our study suggests that COVID-19 does not pose a lasting hurdle for the National TB control efforts among patients who are willing and able to utilise private healthcare. More patient education on the importance of getting tested with prolonged coughing, as well as improving referral systems and provider training within the private and public healthcare sectors are needed in our study settings. The WHO calls for multisectoral and intersectoral engagement in the fight against TB, and our findings support evidence from other high-burden settings that private sector provider engagement is critical.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Acknowledgments

We would like to thank the Abts Associates team, particularly Elaine Baruwa and all the field staff and providers that participated in this survey. We thank the COVET study team and the McGill International TB centre, particularly Caroline Vadnais, for sustained support throughout the process of this study. The authors also thank Guy Stallworthy, Sameer Kupta and Kayla Laserson of the Bill and Melinda Gates Foundation for their support.

Appendix

View this table:
  • View inline
  • View popup
  • Download powerpoint
Appendix 1:

Concurrent mixed methods and participant recruitment flow chart

View this table:
  • View inline
  • View popup
Appendix 2:

Quota sample distribution by site

View this table:
  • View inline
  • View popup
  • Download powerpoint
Appendix 3:

Characteristics of respondents and non-respondents

View this table:
  • View inline
  • View popup
Appendix 4:

Average number of encounters by type of provider seen first

View this table:
  • View inline
  • View popup
Appendix 5:

Selected qualitative themes and example quotes

Footnotes

  • Funding: This work was supported by the Bill and Melinda Gates Foundation (COVID Impact on Private Health Markets Grant INV-022420 to MP and JD). The study was implemented by the USAID-funded SHOPS Plus Project in Nigeria (Contract #: AID-OAA-A-15-00067, https://www.usaid.gov/). EB, LR, BOF, AA and BJ were affiliated with the SHOPS Plus project and not direct recipients of a USAID contract. None of the co-authors are employees of the funding agency. The funders provided inputs on the study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript.

References

  1. 1.↵
    >World Health Organization, Global tuberculosis report 2022. 2022.
  2. 2.
    Kirby, T., Global tuberculosis progress reversed by COVID-19 pandemic. The Lancet Respiratory Medicine, 2021.
  3. 3.↵
    Wingfield, T., et al., Tackling two pandemics: a plea on World Tuberculosis Day. The Lancet Respiratory Medicine, 2020. 8(6): p. 536–538.
    OpenUrl
  4. 4.↵
    Organization, W.H., Gear up to end TB: introducing the end TB strategy. 2015, World Health Organization.
  5. 5.↵
    Odusanya, O.O. and J.O. Babafemi, Patterns of delays amongst pulmonary tuberculosis patients in Lagos, Nigeria. BMC public health, 2004. 4(1): p. 1–5.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Oga-Omenka, C., et al., Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria-A retrospective cohort study. PloS one, 2019. 14(4): p. e0215542.
    OpenUrlPubMed
  7. 7.↵
    Ukwaja, K.N., et al., Healthcare-seeking behavior, treatment delays and its determinants among pulmonary tuberculosis patients in rural Nigeria: a cross-sectional study. BMC health services research, 2013. 13(1): p. 1–9.
    OpenUrl
  8. 8.↵
    Getnet, F., et al., Delay in diagnosis of pulmonary tuberculosis in low-and middle-income settings: systematic review and meta-analysis. BMC pulmonary medicine, 2017. 17(1): p. 1–15.
    OpenUrl
  9. 9.↵
    Bajehson, M., et al., Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria. PloS one, 2019. 14(11): p. e0225165.
    OpenUrl
  10. 10.
    Lin, X., et al., Dose–response relationship between treatment delay of smear-positive tuberculosis patients and intra-household transmission: a cross-sectional study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008. 102(8): p. 797–804.
    OpenUrlCrossRefPubMed
  11. 11.
    Tedla, K., et al., Delay in treatment initiation and its association with clinical severity and infectiousness among new adult pulmonary tuberculosis patients in Tigray, northern Ethiopia. BMC Infectious Diseases, 2020. 20(1): p. 1–10.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Virenfeldt, J., et al., Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. BMJ open, 2014. 4(6): p. e004818.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Hanson, C., et al., Finding the missing patients with tuberculosis: lessons learned from patient-pathway analyses in 5 countries. The Journal of infectious diseases, 2017. 216(suppl_7): p. S686-S695.
    OpenUrlPubMed
  14. 14.↵
    Ku, C.-C., et al., Patient pathways of tuberculosis care-seeking and treatment: an individual-level analysis of National Health Insurance data in Taiwan. BMJ global health, 2020. 5(6): p. e002187.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    World Health Organization, The End TB Strategy. 2015.
  16. 16.↵
    Mistry, N., et al., Pulmonary tuberculosis in Patna, India: Durations, delays, and health care seeking behaviour among patients identified through household surveys. Journal of epidemiology and global health, 2017. 7(4): p. 241-248.
    OpenUrl
  17. 17.↵
    Lestari, B.W., et al., Patient pathways and delays to diagnosis and treatment of tuberculosis in an urban setting in Indonesia. The Lancet Regional Health-Western Pacific, 2020. 5: p. 100059.
    OpenUrl
  18. 18.↵
    Yellappa, V., et al., Patients pathways to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study from a south Indian district. BMC public health, 2017. 17(1): p. 1–10.
    OpenUrlCrossRefPubMed
  19. 19.↵
    World Health Organization, Engaging private health care providers in TB care and prevention: a landscape analysis 2020 Update. 2020, World Health Organization.
  20. 20.↵
    Nigeria Centre for Disease Control, COVID-19 Situation Report Weekly Epidemiological Report 64, M.o. Health, Editor. 2022.
  21. 21.↵
    Adewole, O., Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria. Int J Tuberc Lung Dis, 2020. 24(9): p. 981–982.
    OpenUrlCrossRefPubMed
  22. 22.
    McQuaid, C.F., et al., The impact of COVID-19 on TB: a review of the data. The International Journal of Tuberculosis and Lung Disease, 2021. 25(6): p. 436–446.
    OpenUrl
  23. 23.↵
    Odume, B., et al., Impact of COVID-19 on TB active case finding in Nigeria. Public Health Action, 2020. 10(4): p. 157.
    OpenUrl
  24. 24.↵
    Oga-Omenka, C., et al., Tuberculosis service disruptions and adaptations during the first year of the COVID-19 pandemic in the private health sector of two urban settings in Nigeria—A mixed methods study. PLOS Global Public Health, 2023. 3(3): p. e0001618.
    OpenUrl
  25. 25.↵
    Oga-Omenka, C., et al. Commentary: Lessons from the COVID-19 global health response to inform TB case finding. in Healthcare. 2021. Elsevier.
  26. 26.
    Visca, D., et al., Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology, 2021.
  27. 27.
    Udwadia, Z.F., et al., COVID-19-Tuberculosis interactions: when dark forces collide. Indian Journal of Tuberculosis, 2020.
  28. 28.↵
    Zimmer, A.J., et al., Tuberculosis in times of COVID-19. J Epidemiol Community Health, 2021.
  29. 29.↵
    Chijioke-Akaniro, O., et al., Strategic Engagement of Private Facilities to Increase Public-Private Mix (PPM) Contribution to Nigeria Tuberculosis Case Notification. Journal of Tuberculosis Research, 2022. 10(3): p. 99–110.
    OpenUrl
  30. 30.↵
    SHOPS Plus, SHOPS Plus Tuberculosis Program in Nigeria. 2021: Abuja, Nigeria.
  31. 31.↵
    Bello, S., et al., Empirical evidence of delays in diagnosis and treatment of pulmonary tuberculosis: systematic review and meta-regression analysis. BMC public health, 2019. 19(1): p. 1–11.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Oga-Omenka, C., et al., Understanding the gaps in DR-TB care Cascade in Nigeria: a sequential mixed-method study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020. 21: p. 100193.
    OpenUrl
  33. 33.↵
    Subbaraman, R., T. Jhaveri, and R.R. Nathavitharana, Closing gaps in the tuberculosis care cascade: an action-oriented research agenda. Journal of clinical tuberculosis and other mycobacterial diseases, 2020. 19: p. 100144.
    OpenUrl
  34. 34.↵
    Sreeramareddy, C.T., et al., Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infectious Diseases, 2009. 9(1): p. 91.
    OpenUrlCrossRefPubMed
  35. 35.↵
    World Health Organization, WHO Guidelines Approved by the Guidelines Review Committee, in WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. 2016, World Health Organization 2016.: Geneva.
  36. 36.↵
    Babatunde, O.I., et al., Determinants of treatment delays among pulmonary tuberculosis patients in Enugu Metropolis, South-East, Nigeria. Health, 2015. 7(11): p. 1506.
    OpenUrl
  37. 37.↵
    Kim, J., S. Keshavjee, and R. Atun, Health systems performance in managing tuberculosis: analysis of tuberculosis care cascades among high-burden and non-high-burden countries. Journal of Global Health, 2019. 9(1).
  38. 38.↵
    Oga-Omenka, C., et al., Factors influencing diagnosis and treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review. BMJ global health, 2020. 5(7): p. e002280.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    National Bureau of Statistics, Demographic Statistics Bulletin. 2021, National Bureau of Statistics Nigeria.
  40. 40.↵
    Groves, R.M., et al., Survey methodology. 2011: John Wiley & Sons.
  41. 41.↵
    Valliant, R. and J.A. Dever, Survey weights: a step-by-step guide to calculation. 2018: Stata Press College Station, TX.
  42. 42.↵
    Cazabon, D., et al., Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. International Journal of Infectious Diseases, 2017. 56: p. 111–116.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Stallworthy, G., H.M. Dias, and M. Pai, Quality of tuberculosis care in the private health sector. Journal of clinical tuberculosis and other mycobacterial diseases, 2020. 20: p. 100171.
    OpenUrl
  44. 44.↵
    Beyeler, N., J. Liu, and M. Sieverding, A systematic review of the role of proprietary and patent medicine vendors in healthcare provision in Nigeria. PLoS One, 2015. 10(1): p. e0117165.
    OpenUrlCrossRefPubMed
  45. 45.↵
    Konduri, N., E. Delmotte, and E. Rutta, Engagement of the private pharmaceutical sector for TB control: rhetoric or reality? Journal of pharmaceutical policy and practice, 2017. 10(1): p. 1–13.
    OpenUrl
  46. 46.↵
    Prach, L.M., et al., Care-seeking at patent and proprietary medicine vendors in Nigeria. BMC Health Services Research, 2015. 15(1): p. 1–12.
    OpenUrl
  47. 47.↵
    Das, J., et al., Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. The Lancet infectious diseases, 2015. 15(11): p. 1305–1313.
    OpenUrlCrossRefPubMed
  48. 48.
    Lönnroth, K., et al., Public-private mix for DOTS implementation: what makes it work? Bulletin of the World Health Organization, 2004. 82: p. 580–586.
    OpenUrlPubMedWeb of Science
  49. 49.↵
    Pradhan, A., et al., What’outliers’ tell us about missed opportunities for tuberculosis control: a cross-sectional study of patients in Mumbai, India. BMC public health, 2010. 10(1): p. 1–9.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Rosapep, L.A., et al., Tuberculosis care quality in urban Nigeria: A cross-sectional study of adherence to screening and treatment initiation guidelines in multi-cadre networks of private health service providers. PLOS Global Public Health, 2022. 2(1): p. e0000150.
    OpenUrl
  51. 51.↵
    Oga-Omenka, C., et al., Ease and equity of access to free DR-TB services in Nigeria-a qualitative analysis of policies, structures and processes. International Journal for Equity in Health, 2020. 19(1): p. 1–13.
    OpenUrl
  52. 52.↵
    Almeida, C.P.B.d., E.C. Skupien, and D.R. Silva, Health care seeking behavior and patient delay in tuberculosis diagnosis. Cadernos de saude publica, 2015. 31: p. 321–330.
    OpenUrl
  53. 53.↵
    Meintjes, G., et al., Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC infectious diseases, 2008. 8(1): p. 1–8.
    OpenUrlCrossRefPubMed
  54. 54.↵
    Van der Werf, M., et al., Health care seeking behaviour for tuberculosis symptoms in Kiev City, Ukraine. The international journal of tuberculosis and lung disease, 2006. 10(4): p. 390–395.
    OpenUrl
  55. 55.↵
    Meyssonnier, V., et al., Factors associated with delayed tuberculosis diagnosis in China. The European Journal of Public Health, 2013. 23(2): p. 253–257.
    OpenUrlCrossRefPubMed
  56. 56.
    Tattevin, P., et al., Factors associated with patient and health care system delay in the diagnosis of tuberculosis in France. The international journal of tuberculosis and lung disease, 2012. 16(4): p. 510–515.
    OpenUrl
  57. 57.↵
    He, Y., et al., Total delay in treatment among tuberculous meningitis patients in China: a retrospective cohort study. BMC infectious diseases, 2017. 17(1): p. 1–5.
    OpenUrlCrossRefPubMed
  58. 58.↵
    Field, N., et al., Missed opportunities in TB diagnosis: a TB process-based performance review tool to evaluate and improve clinical care. BMC Public Health, 2011. 11(1): p. 1–7.
    OpenUrlCrossRefPubMed
  59. 59.
    Sendagire, I., et al., Long delays and missed opportunities in diagnosing smear-positive pulmonary tuberculosis in Kampala, Uganda: a cross-sectional study. PLOS one, 2010. 5(12): p. e14459.
    OpenUrlCrossRefPubMed
  60. 60.↵
    Divala, T.H., et al., Missed opportunities for diagnosis and treatment in patients with tuberculosis symptoms: a systematic review. 2020.
  61. 61.↵
    Abimbola, S., et al., Transaction costs of access to health care: Implications of the care-seeking pathways of tuberculosis patients for health system governance in Nigeria. Global Public Health, 2015. 10(9): p. 1060–1077.
    OpenUrl
  62. 62.↵
    Subbaraman, R., et al., Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS medicine, 2019. 16(2): p. e1002754.
    OpenUrl
  63. 63.↵
    Millen, S.J., et al., The effect of diagnostic delays on the drop-out rate and the total delay to diagnosis of tuberculosis. PloS one, 2008. 3(4): p. e1933.
    OpenUrlCrossRefPubMed
  64. 64.↵
    Teo, A.K.J., et al., Determinants of delayed diagnosis and treatment of tuberculosis in Cambodia: a mixed-methods study. Infectious diseases of poverty, 2020. 9: p. 1–12.
    OpenUrl
  65. 65.↵
    Hazarika, I., Role of private sector in providing tuberculosis care: evidence from a population-based survey in India. Journal of global infectious diseases, 2011. 3(1): p. 19.
    OpenUrl
  66. 66.↵
    Pardeshi, G., et al., Tuberculosis patients not covered by treatment in public health services: findings from India’s National Family Health Survey 2015–16. Tropical Medicine & International Health, 2018. 23(8): p. 886–895.
    OpenUrl
  67. 67.↵
    Johansson, E., et al., Gender and tuberculosis control: perspectives on health seeking behaviour among men and women in Vietnam. Health policy, 2000. 52(1): p. 33–51.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    Onyeonoro, U.U., et al., Evaluation of patient satisfaction with tuberculosis Services in Southern Nigeria. Health services insights, 2015. 8: p. HSI.S27177.
    OpenUrl
  69. 69.↵
    Rintiswati, N., et al., Journeys to tuberculosis treatment: a qualitative study of patients, families and communities in Jogjakarta, Indonesia. BMC Public Health, 2009. 9(1): p. 1–10.
    OpenUrlCrossRefPubMed
  70. 70.
    Sadiq, H. and A. Muynck, Health care seeking behaviour of pulmonary tuberculosis patients visiting TB Center Rawalpindi. JOURNAL-PAKISTAN MEDICAL ASSOCIATION, 2001. 51(1): p. 10–15.
    OpenUrl
  71. 71.
    Sreeramareddy, C.T., et al., Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. The International Journal of Tuberculosis and Lung Disease, 2014. 18(3): p. 255–266.
    OpenUrl
  72. 72.↵
    Needham, D.M., et al., Patient care seeking barriers and tuberculosis programme reform: a qualitative study. Health Policy, 2004. 67(1): p. 93–106.
    OpenUrlCrossRefPubMed
  73. 73.
    Fochsen, G., et al., Health care seeking among individuals with cough and tuberculosis: a population-based study from rural India. The international journal of tuberculosis and lung disease, 2006. 10(9): p. 995–1000.
    OpenUrl
  74. 74.↵
    Senkoro, M., et al., Health care-seeking behaviour among people with cough in Tanzania: findings from a tuberculosis prevalence survey. The international journal of tuberculosis and lung disease, 2015. 19(6): p. 640–646.
    OpenUrl
  75. 75.↵
    Needham, D.M., et al., Socio-economic, gender and health services factors affecting diagnostic delay for tuberculosis patients in urban Zambia. Tropical Medicine & International Health, 2001. 6(4): p. 256–259.
    OpenUrl
  76. 76.
    Storla, D.G., S. Yimer, and G.A. Bjune, A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC public health, 2008. 8(1): p. 1–9.
    OpenUrlCrossRefPubMed
  77. 77.↵
    Bronner Murrison, L., et al., How do patients access the private sector in Chennai, India? An evaluation of delays in tuberculosis diagnosis. The International Journal of Tuberculosis and Lung Disease, 2016. 20(4): p. 544–551.
    OpenUrl
  78. 78.↵
    Klinton, J.S., C. Oga-Omenka, and P. Heitkamp, TB and COVID–Public and private health sectors adapt to a new reality. 2020, Elsevier. p. 100199.
  79. 79.↵
    Migliori, G.B., et al., Worldwide effects of coronavirus disease pandemic on tuberculosis services, January– April 2020. Emerging infectious diseases, 2020. 26(11): p. 2709.
    OpenUrlPubMed
Back to top
PreviousNext
Posted June 20, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Individual healthcare-seeking pathways for tuberculosis in Nigeria’s private sector during the COVID-19 pandemic
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Individual healthcare-seeking pathways for tuberculosis in Nigeria’s private sector during the COVID-19 pandemic
Charity Oga-Omenka, Lauren Rosapep, Lavanya Huria, Nathaly Aguilera Vasquez, Bolanle Olusola-Faleye, Mohammad Abdullah Heel Kafi, Angelina Sassi, Chimdi Nwosu, Benjamin Johns, Abdu Adamu, Obioma Chijioke-Akaniro, Chukwuma Anyaike, Madhukar Pai
medRxiv 2023.06.13.23291334; doi: https://doi.org/10.1101/2023.06.13.23291334
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Individual healthcare-seeking pathways for tuberculosis in Nigeria’s private sector during the COVID-19 pandemic
Charity Oga-Omenka, Lauren Rosapep, Lavanya Huria, Nathaly Aguilera Vasquez, Bolanle Olusola-Faleye, Mohammad Abdullah Heel Kafi, Angelina Sassi, Chimdi Nwosu, Benjamin Johns, Abdu Adamu, Obioma Chijioke-Akaniro, Chukwuma Anyaike, Madhukar Pai
medRxiv 2023.06.13.23291334; doi: https://doi.org/10.1101/2023.06.13.23291334

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)